🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

31 results for “Atrium Therapeutics” Clear

  1. PGET

    Atrium Therapeutics

    Osteoarthritis

    phase 3 other terminated

    1 trial

  2. Phlebotomy

    Atrium Therapeutics

    Hemochromatosis

    phase 3 other completed

    1 trial

  3. Phlebotomy and erythrocytapheresis

    Atrium Therapeutics

    Hereditary Hemochromatosis

    phase 3 other active

    1 trial

  4. Ropivacaine HCL

    Atrium Therapeutics

    Renal Carcinoma

    phase 3 small molecule active

    1 trial

  5. Wobenzym® N

    Atrium Therapeutics

    Knee Osteoarthritis

    phase 3 other terminated

    1 trial

  6. eythrocytapheresis

    Atrium Therapeutics

    Pre Operative Autologous Donation

    phase 3 other completed

    1 trial

  7. Carboplatin

    Atrium Therapeutics

    Lung Cancer Stage II

    phase 2 small molecule active

    1 trial

  8. Diclofenac

    Atrium Therapeutics

    Wobenzym

    phase 2 small molecule completed

    1 trial

  9. Elotuzumab

    Atrium Therapeutics

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  10. Low-dose ASA

    Atrium Therapeutics

    Germ Cell Tumor

    phase 2 small molecule active

    1 trial

  11. Metformin Hydrochloride ER

    Atrium Therapeutics

    Sarcoma Metastatic

    phase 2 small molecule active

    1 trial

  12. Nivolumab

    Atrium Therapeutics

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  13. Olutasidenib

    Atrium Therapeutics

    IDH1 Mutation

    phase 2 small molecule active

    1 trial

  14. Vaccine

    Atrium Therapeutics

    Pediatric Cancer

    phase 2 mab active

    1 trial

  15. anastrozole

    Atrium Therapeutics

    Female Breast Carcinoma

    phase 2 small molecule active

    1 trial

  16. IVAC MUTANOME, RBL001/RBL002

    Atrium Therapeutics

    Melanoma

    phase 1 mab completed

    1 trial

  17. Nivolumab

    Atrium Therapeutics

    Brain and Nervous System

    phase 1 small molecule completed

    1 trial

  18. Novel Supplement Based Therapy

    Atrium Therapeutics

    Small Intestinal Bacterial Overgrowth

    phase 1 other terminated

    1 trial

  19. RBL001/RBL002

    Atrium Therapeutics

    Melanoma

    phase 1 mab completed

    1 trial

  20. SAR441000

    Atrium Therapeutics

    Metastatic Neoplasm

    phase 1 small molecule terminated

    1 trial

  21. Phenoxybenzamine

    Atrium Therapeutics

    Pheochromocytoma

    approved small molecule completed

    1 trial

  22. Rivastigmine

    Atrium Therapeutics

    Parkinson's Disease

    approved small molecule terminated

    1 trial

  23. Abciximab local infusion

    Atrium Therapeutics

    Acute Anterior Myocardial Infarction

    small molecule completed

    1 trial

  24. Cranberry

    Atrium Therapeutics

    Endotoxemia

    other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources